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Abstract
Purpose This review aims to provide insight into the
factors that influence quantification of glucose metabolism
by FDG PET images in oncology as well as their influence
on repeated measures studies (i.e. treatment response
assessment), offering improved understanding both for
clinical practice and research.
Methods Structural PubMed searches have been performed
for the many factors affecting quantification of glucose
metabolism by FDG PET. Review articles and references
lists have been used to supplement the search findings.
Results Biological factors such as fasting blood glucose
level, FDG uptake period, FDG distribution and clearance,
patient motion (breathing) and patient discomfort (stress) all
influence quantification. Acquisition parameters should be
adjusted to maximize the signal to noise ratio without
exposing the patient to a higher than strictly necessary
radiation dose. This is especially challenging in pharmaco-
kinetic analysis, where the temporal resolution is of
significant importance. The literature is reviewed on the
influence of attenuation correction on parameters for glucose
metabolism, the effectof motion, metal artefactsand contrast
agents on quantification of CTattenuation-corrected images.
Reconstruction settings (analytical versus iterative recon-
struction, post-reconstruction filtering and image matrix
size) all potentially influence quantification due to artefacts,
noise levels and lesion size dependency. Many region of
interest definitions are available, but increased complexity
does not necessarily result in improved performance.
Different methods for the quantification of the tissue of
interest can introduce systematic and random inaccuracy.
Conclusions This review provides an up-to-date overview
of the many factors that influence quantification of glucose
metabolism by FDG PET.
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Introduction
Positron emission tomography (PET, see Table 1 for all
abbreviations in this paper) using 2-[
18F]-2-deoxy-D-
glucose (FDG) is an established imaging modality in
oncology [1]. Although in daily practice visual inspection
of FDG PET images is used for diagnosis and assessment
of response to therapy, it has been shown that (semi-)
quantitative analysis allows an objective complement to
visual interpretation of lesions [2–4]. Results of this analysis
might be used for individual tailoring of therapy, since
increased FDG uptake usually corresponds to a dismal course
of the disease. Repeated measurements can be used in early
response assessment, valuable for further individualization of
therapy [5]. Generally, lesions are quantified using the
standardized uptake value of FDG [SUV, i.e. the FDG
activity concentration at a single time point normalized to the
administered activity (AA) and a measure for distribution
volume such as body weight] and treatment response is
assessed by the relative change between a baseline and a
follow-up scan during the course of therapy (ΔSUV).
Although the results of the first trials have been published
in which the performance of individually tailored therapy
based on early response to neoadjuvant treatment is investi-
gated [6] and new trials are currently being undertaken, the
multiple factors influencing the quantification of glucose
metabolism by FDG PET are still under discussion [7–9].
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quantification of parameters of glucose metabolism, a
variety of factors also influence the reproducibility of these
parameters [10, 11]. Quantification of glucose metabolism
by FDG PET is not only dependent on biological properties
of the disease under investigation, but also on methodolog-
ical aspects of patient preparation, image acquisition,
reconstruction, region of interest (ROI) definition and
methods of parameter computation. To be able to perform
multicentre studies or meta-analysis, but also to apply
results of studies in clinical practice, the influence of these
factors should be minimized by standardization. This has
led to the development of consensus recommendations by
the European Organization for Research and Treatment of
Cancer (EORTC) [12], the National Cancer Institute (NCI)
[13] and the Netherlands Society of Nuclear Medicine
(NEDPAS) [14]. The Society of Nuclear Medicine has
agreed on procedure guidelines for tumour imaging but
conclude that optimal methods for semiquantitative mea-
surements need further elucidation [15].
This review aims to give a theoretical background
illustrated by up-to-date publications on the influence of
methodological factors influencing quantification of FDG
PET. It will not merely focus on the semiquantitative
parameter SUV, but also include fully quantitative param-
eters such as the glucose metabolic rate (MRglc) and the
pharmacokinetic rate constants of two-compartment model
analysis. Hardware issues influencing scanner sensitivity,
such as detector crystal material, photon energy window,
coincidence timing window, detector ring diameter and
axial length of the field of view (FOV), are not addressed in
this review. Several other factors are considered outside the
Abbreviation Definition
AA Administered activity
AC Attenuation correction
BAT Brown adipose tissue
BSA Body surface area
BW Body weight
FBP Filtered backprojection
FDG 2-[
18F]-2-deoxy-D-glucose
FOV Field of view
FWHM Full-width at half-maximum
glc Glucose
ICC Intraclass correlation coefficient
IDIF Image-derived input function
K1 Rate constant of forward transmembranous transport
k2 Rate constant of reversed transmembranous transport
k3 Rate constant of cytoplasmic phosphorylation
k4 Rate constant of cytoplasmic dephosphorylation
Ki Net influx rate constant
LBM Lean body mass
LCFDG Lumped constant of FDG
LOR Line of response
MAC Measured attenuation correction
MR Metabolic (phosphorylation) rate
NEC Noise equivalent count rate
NEMA National Electrical Manufacturers Association
OSEM Ordered subsets expectation maximization
PET Positron emission tomography
PVE Partial volume effect
ROI Region of interest
RTL Relative threshold level
SAC Segmented attenuation correction
SNR Signal to noise ratio
SUV Standardized uptake value (see Table 3)
Vb Blood volume fraction
Table 1 Commonly used
abbreviations
Eur J Nucl Med Mol Imaging (2010) 37:1408–1425 1409scope of this study; these are: methodological errors, such as
invalid cross-calibration, asynchronous clocks, omission of
decay correction for the time period between calibration and
start of the PET scan, low precision of plasma glucose
measurement, failure to measure residual activity concentra-
tion of the infusion system or paravenous infiltration of FDG
and factors inextricably linked to the non-specific targeting
of FDG (e.g. infection, post-radiotherapy inflammation).
Patient preparation and image acquisition
Biological factors affecting quantification
Several biological factors affecting quantification, such as
fasting plasma glucose level, uptake period, FDG distribu-
tion and clearance, patient motion (breathing) and patient
discomfort (stress), all deserve attention at the time of
patient preparation, FDG administration and distribution
and image acquisition.
Blood glucose level
High blood glucose levels, due to a non-fasting state or
diabetes mellitus, interfere with FDG uptake in malignant
lesions. The transmembranous glucose transport facilitators
(GLUT), albeit overexpressed in many cancers, can be
saturated by an excess of unlabelled glucose. This dimin-
ishes FDG uptake as glucose and FDG both compete for
the binding sites of transporters and enzymes, leading to
zero-order kinetics. In patients without any known form of
glucose intolerance it is shown in two consecutive scans
that the SUV, using body weight as a measure of
distribution volume, is significantly lower in the loaded
state (serum glucose >8.0 mmol∙l
−1) in both head and neck
cancer (SUVBW=6.9 vs 4.0, p<0.02) [16] and bronchial
carcinoma (SUVBW=5.07 vs 2.84, p<0.001) [17] compared
to the fasting state (<6.0 mmol∙l
−1). In contrast to the
reduction of tumour uptake, skeletal muscle accumulates
more FDG, resulting in blurring of tumour margins and less
clear localization of lesions [16]. Also Patlak-based net
influx rate constants (Ki) of the lesions decrease markedly
in the glucose loaded state (mean −25%, p<0.05), while
MRglc is on average 36% higher. This paradoxical increase
in MRglc might be due to the fact that the authors assumed
the same value for the relative affinity of the biological
system to FDG and glucose (‘lumped constant’, LC) in
both states to compute MRglc from Ki, which is likely
untrue [18].
The effect of hyperglycaemia has clear impact on visual
interpretation of FDG PET images as it results in a reduced
detection rate of malignancies [19], but it also has a major
effect on quantification. Therefore, hyperglycaemia should
be a reason to reschedule the procedure. Correction of
hyperglycaemia by insulin directly prior to the FDG
injection is dissuaded, because hyperinsulinaemia increases
the translocation of GLUT4 thereby rapidly and efficiently
shunting FDG to organs with a high density of insulin
receptors (e.g. skeletal and cardiac muscles) [19]. When
FDG injection is postponed to 1 h after insulin administra-
tion (up to a serum glucose below 8.0 mmol∙l
−1)i n
hyperglycaemic diabetic patients, no differences between
normoglycaemic non-diabetics and hyperglycaemic (insulin-
corrected) diabetics are found in SUV, using lean body
mass as measure for distribution volume (SUVLBM), in
lungs, liver, muscles, myocardium or suspected pulmonary
lesions [20]. However, recently a standardized protocol of
intravenous insulin at least 1 h prior to FDG injection led to
an unacceptable biodistribution in 25% of diabetic cancer
patients (increased muscle uptake and decreased liver
uptake). In these patients the interval between insulin and
FDG injection was significantly shorter than in the patients
with a normal biodistribution (65.7 vs 80.2 min, p<0.01)
[21]. Metformin strongly increases the SUV of the small
and large intestines, potentially decreasing the detection
sensitivity for malignant lesions, but the influence on lesion
quantification is not described [22]. To prevent hyper-
glycaemia in non-diabetic patients, guidelines [12–14]
recommend that patients should have fasted at least 4 h,
but preferably 6 h before administration of FDG. When
blood glucose levels are well outside physiological ranges
(e.g. >11 mmol∙l
−1 [14]) the scan should be postponed. We
use a stricter cut-off for research purposes (8.0 mmol∙l
−1).
Uptake period
Typically, PET acquisition is performed 45–60 min after
FDG injection, based on the fact that FDG activity
concentrations become constant within the first hour after
tracer injection in normal tissues. In malignancies, however,
it has been shown that for some tumour types FDG
concentration continues to increase up to 4–5 h after
injection and that constant FDG activity concentrations
are rarely reached within the first hour after injection.
Between 60 and 90 min post-injection, it is not uncommon
for a lesion to further increase SUVas much as one tenth of
the value reached 10 h post-injection [23]. Since a further
increase in FDG activity concentration 1 h after injection is
rare in normal tissues [24], it has been hypothesized that
dual-time-point imaging (45 and 90 min post-injection)
might improve detection rates of lesions with high glucose
metabolism by increasing tumour to background ratios.
Therefore, for response monitoring studies using SUVs it is
highly important to keep the uptake period of FDG within
narrow limits (55–65 min) [13, 14].
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To optimize the distribution of FDG throughout the body,
international guidelines recommend prehydration (0.5 l) of
the patient to ensure excretion of FDG from healthy
background tissue, which may be further enhanced by
furosemide-induced forced diuresis. This might be of special
value when the pelvis or kidney regions are of interest [12–
14]. Median SUV values of tumours are lower if furosemide
is used. However, the total fraction of excreted activity is not
different if diuretics are used, but is significantly higher early
after injection for the furosemide group leading to improved
image quality and reducing patient radiation exposure [25].
Therefore, it seems important when comparing parameters
for glucose metabolism that the use of (loop) diuretics should
be taken into account. A practical disadvantage of using
forced diuresis during dynamic acquisition is that measures
should be taken to avoid premature termination of the
acquisition due to urinary urgency.
Patient (periodic) motion
Apart from exercise-induced increased muscle uptake during
the uptake period, the effect of motion during acquisition has
consequences for lesion localization (e.g. spatial mismatch
around the diaphragm due to breathing) and causes smearing
of the lesion activity concentration within the volume of
movement. Consequently, the lesion metabolic volume is
overestimated and the SUV is underestimated. Moreover,
tissue inhomogeneity is similarly smeared, leading to loss of
spatial heterogeneity. The magnitude of the decrease of
recovered activity concentrations depends most markedly on
lesion size and amplitude of motion and to a lesser extent on
the motion frequency. Recovered activity concentrations can
be increased by better lesion volume estimation by a motion
correction algorithm. Verified in nine lung cancer patients, this
algorithm reduces the estimated lesion volume by 15%
l e a d i n gt oa ni n c r e a s eo ft h em e a nS U Vi nt h eR O I( S U V mean)
by 5% [26]. Different other techniques may be applied to
improve recovery of activity concentration in periodically
moving lesions such as gated PET/CT (in which data are only
acquired during a certain respiratory phase), respiratory
correlated dynamic PET/CT (by summing the sinograms of
images of a particular breathing phase selected using a point
source) or deep inspiration breath-hold PET/CT [27].
During dynamic acquisition, non-periodic patient move-
ment can have major influence on measured parameters,
since the lesion can “move into” the ROI usually defined in
the last time frame(s). Consequently, activity concentrations
of the lesion are underestimated for the period before patient
movement due to a mispositioned ROI. In the time frames in
which the lesion of interest is visible the ROI can be
realigned, but during the early time frames this is often
impossible due to noisy images or insufficient tissue to blood
contrast. Patient movement therefore should be prevented
and monitored during acquisition, the original position
should be restored as quickly as possible and any movement
should be noted including time at which it occurred.
IfCT-basedattenuationcorrection(AC)isused,anyspatial
mismatch will lead to incorrect amplification of measured
activity concentrations, leading to unreliable values for lesion
quantification (differences of around 10% in SUV [28, 29]
due to breathing, smallest for free breathing CT [28]).
Patient discomfort
Patient stress or cold during the distribution period
increases uptake of FDG in muscle and brown adipose
tissue (BAT) [30–32]. This can lower detection sensitivity
(by lowering contrast) and specificity (by increasing the
number of false-positive lesions) of the images and might
affect quantification [14, 33]. Factors known to increase
FDG uptake in BAT such as exposure to cold [31, 32, 34–
36] should be prevented by exposing patients to thermo-
neutral conditions. Medication such as the beta-adrenergic
blocking agent propranolol [31, 36–39], reserpine [36] and
the opiate fentanyl [40] all prevent FDG uptake in BAT, but
the effect of benzodiazepines seems doubtful [35, 36, 40,
41]. The NEDPAS guidelines [14] suggest considering the
use of benzodiazepines to reduce muscle uptake when
tumours in the head and neck region are expected and state
that there is no place for it to reduce uptake in BAT.
Technical factors affecting quantification
At the time of data acquisition, several factors influence
quantification. These include scan acquisition parameters
(such as acquisition mode, scan duration, bed overlap and
administered FDG activity), time frame duration in dynamic
acquisitions, factors related to attenuation correction (such as
motion and the use of CTcontrast agents) and other forms of
data correction. Most of these settings are based on the
performance of the scanner and should be measured
according to the NEMA (National Electrical Manufacturers
Association) NU2–2007 standard [42]( T a b l e2).
Acquisition parameters
The choices of acquisition parameters are closely interrelated
and are based on trade-offs between signal to noise ratio
(SNR) and radiation safety, financial issues (e.g. patient
throughput, costs of FDG), patient comfort and logistics.
Increasing the sensitivity of the PET scanner by using 3-D
acquisition (instead of 2-D acquisition using lead or tungsten
septa between crystal rings), increasing scan duration,
enlarging bed overlap and raising the administered FDG
Eur J Nucl Med Mol Imaging (2010) 37:1408–1425 1411activity (below the amount that results in count rates
exceedingthemaximumcountratecapabilitiesofthescanner)
all improve SNR. Removing the interplane septa from the
PET scanner (i.e. changing from 2-D to 3-D mode) typically
leads to a four- to eightfold increase in sensitivity but also
increases the number of detected scattered and random
photons. Generally, the peak noise equivalent count rate
(NEC)isobtainedataloweractivityconcentrationin3-Dthan
in 2-D as expected from the behaviour of the (increased) true
coincidence rate. As a result the SNR (for a uniform cylinder
SNR /
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
NEC
p
[43]) will be higher when operating in 3-D
versus 2-D mode for the low activity concentration range.
Recommendations for administered FDG activity therefore
should be based on acquisition mode (2-D or 3-D), scan
duration and bed overlap, rather than on pre-determined
diagnostic reference levels [12]. The NCI guidelines recom-
mend a total administered FDG activity of 5.18–
7.77 MBq∙kg
−1 [13], and the NEDPAS recommendations
advise 27.5 MBq∙min∙kg
−1 (for 2-D and ≤25% bed overlap),
13.8 MBq∙min∙kg
−1 (for 3-D and ≤25% bed overlap) or
6.9 MBq∙min∙kg
−1 (for 3-D and 50% bed overlap). For a 3-D
acquisition of a 70-kg patient with 4 min per bed position
(with 25% bed overlap), it recommends approximately
242 MBq (±10%) to be administered, which corresponds to
an effective absorbed dose of 4.6 mSv of the FDG
(0.019 mSv∙MBq
−1 [44]). Reducing scan duration therefore
necessitates increased administered FDG activity to maintain
SNR. Increasing acquisition time effectively maintains the
quality (SNR) of FDG PET scans of heavier patients,
agreeing with the hypothesis that increasing body weight
increases the fractions of random and scatter coincidences
[45, 46]. Increasing administered FDG activity does not
improve SNR in a study, explained by the fact that it was
likely to saturate count rates of the equipment [47].
Time frame duration
For dynamic acquisition, activity concentration changes are
largest during the first minutes of acquisition (bolus transit)
but depend on the rate of FDG infusion, distribution and
clearance. Therefore, when partitioning list-mode data or
using pre-defined time frames, one should consider a high
temporal resolution for this period, especially important for
pharmacokinetic analysis of two-compartment models.
Improvement of temporal resolution inherently decreases
the count accuracy per time frame, since the (approximate)
Poisson distribution of count statistics (for prompt coinci-
dences) dictates a relative standard deviation dependent on
the inverse square root of the observed counts. As the
choice of framing and the duration of FDG infusion are
related, it is impossible to give general recommendations.
Generally, for scanners with low sensitivity, time frame
durations should be longer and consequently the rate of
FDG infusion slower. The choices of different groups using
dynamic acquisition for oncological purposes can be found
elsewhere [48–50] (Fig. 1).
Attenuation correction
Correction for photon attenuation is necessary since
positron annihilation photons interact with surrounding
tissues (mainly Compton scattering, to a lesser extent
photoelectric effect). Before the introduction of combined
PET/CT, attenuation correction was applied by transmission
imaging of the subject with an external rotating isotope
source, either positron emitters (e.g.
68Ga using its mother
isotope
68Ge) or single photon emitters (e.g.
57Co or
137mBa
using its mother isotope
137Cs). Since photon attenuation is
dependent on the photon energy, the latter two require
scaling to obtain transmission sinograms adapted to
511 keV photons. The attenuation sinogram, the ratio of a
transmission scan and a scan without an object in the FOV
(blank scan), is used to correct the emission sinogram,
which is subsequently reconstructed to an image. Since the
introduction of PET/CT, the spatial distribution of the linear
attenuation coefficients can be obtained using the CT
scanner. Advantages of CT AC are: reduction in total scan
time, lower noise in the transmission sinograms and no
Table 2 NEMA properties of currently commercially available modern PET/CT scanners
Manufacturer: model Crystal
material
Axial FOV
(mm)
Transaxial spatial
resolution
a (mm)
Sensitivity in centre
of FOV (cps∙kBq
−1)
Peak NEC (1R) (kcps)
General Electric: Discovery
PET/CT 690 [121]
BGO 157 4.8 6.7 131.1 @ 28.5 kBq∙cm
−3
Philips: Gemini TF PET/CT [122] LYSO 180 4.8 6.6 125 @ 17.4 kBq∙cm
−3
Siemens:
b Biograph mCT [123] LSO 162 (218) 4.2 (4.1) 4.5 (8.1) 93 @ 34 kBq∙cm
−3
(161 @ 31 kBq∙cm
−3)
BSO bismuth germanium oxide, L(Y)SO lutetium (yttrium) oxyorthosilicate, NEMA according to the National Electrical Manufacturers
Association standard NU 2–2007 [42], 1R computed for a noise-free estimation of randoms. Other abbreviations are explained in Table 1
aAverage measured FWHM 1 cm from centre of the FOV
bThe Siemens Biograph mCT has an extension from three to four detector rings. Properties for this extended FOV are given in parenthesis
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Finally, they can be acquired after tracer injection, choosing
the energy window around the CT photon peak to exclude
the 511 keV photons (radionuclide-based transmission
scans suffer from contamination by emission photons
unless the transmission data are acquired before the PET
tracer is administered to the patient). CT AC however leads
to extra challenges: the use of polyenergetic Bremsstrah-
lung photons with energy much lower than 511 keV (X-ray
tube potential difference usually ∼130 kV leading to photon
energy ranging from 40 to 130 keV, effective energy ∼70–
80 keV), artefacts due to spatial mismatches with PET or
metal objects, effects of CT-enhancing contrast and arte-
facts due to truncation and beam hardening [51].
Conversion of the X-ray to 511 keV linear attenuation
coefficients can be performed by either segmentation,
scaling or dual X-ray imaging. By segmentation, regions
of different material types are identified for which linear
attenuation coefficients for 511 keV photons are known.
Linear scaling of X-ray linear attenuation coefficients can
be performed as long as Compton scattering is the major
determinant of attenuation. However, at CT photon energies
the photoelectric effect plays a significant role for high
atomic number elements (e.g. calcium in bone, iodine or
barium in contrast agents with atomic numbers of 20, 53
and 56, respectively) in which case hybrid or bilinear
scaling is appropriate [51]. Finally, linear attenuation
coefficients can be measured at two tube potential differ-
ences, enabling the separation of attenuation due to the
Compton scattering and the photoelectric effect. In practice,
no significant difference in quantification of malignant
lesions is found comparing CT-based attenuation correction
with segmented AC (SAC) using transmission imaging [28]
or between measured (MAC) and segmented (SAC)
attenuation correction using transmission imaging [29].
CT artefacts due to metal objects and attenuation due to
iodine-containing CT contrast agents might influence lesion
quantification. Multiple studies have found a negligible
change of the SUV in a variety of malignancies varying
from +2.8% to +4% [52–55]. This small effect surprisingly
disappears after chemotherapy [52]. The SUVmean signifi-
cantly increases in the (normal) aorta (+15%), kidneys
(+13%), liver (+11%), spleen (+10%) and inferior caval
vein (+12%) [52]. This might be of relevance when the
plasma time-activity concentration curve for pharmacoki-
netic analysis is image derived (IDIF): a positive bias in the
input function leads to underestimation of MRglc. Around
metal prosthesis, CT AC leads to an underestimation of
FDG activity concentration by <6% [28].
Finally, truncation artefacts, due to a smaller transaxial
FOV of CT than that of PET, lead to incorrect attenuation
correction if there are tissues outside the CT FOV.
Therefore, it is recommended to scan a patient with arms
up except for head and neck imaging. Usually the degree of
truncation is small and therefore no major effects on
quantification are expected. Lowering the arms also causes
beam hardening (structures of higher density cause atten-
uation of low-energy photons of the polyenergetic X-ray
bundle) and scatter-induced artefacts. These can influence
quantification up to 11–15% [51].
Other data corrections
Apart from attenuation correction, other corrections must be
applied before an image can be quantified. These are:
normalization, correction for random coincidences, correc-
tion for scattered radiation, correction for dead time and
cross-calibration with a dose calibrator or well counter.
Remaining differences in detection sensitivity that have
not been corrected in the setup procedure are corrected by
Fig. 1 Dynamic framing dura-
tion in three groups [48–50]
performing dynamic oncological
FDG PET for pharmacokinetic
two-compartment modelling.
Abbreviations are explained in
Table 2. *Duration of a bolus is
a few seconds
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exposed to the same amount of radiation by a rotating
source or a cylinder with a uniform activity concentration.
The measured counts of each detector pair (line of
response, LOR), which should all be equal, are corrected
by normalization factors, which are used to scale the
number of counts of each detector pair to correct the
emission sinogram. Using 3-D acquisition poses a new
challenge for this, since the number of LORs are high
(order of 10
8); therefore, to obtain enough counts per LOR
long normalization procedures seem necessary. For this
reason modified methods have been developed. Instead of
using the acquired number of counts in each LOR
separately, a factorization into different components is
being made (component-based normalization). These com-
ponents are the individual crystal detection efficiencies,
geometrical factors which account for differences in the
distance between detectors and their exposed face and the
position of crystals in a detector block [56, 57].
Random coincidences arise when photons of two
unrelated positron annihilations are detected within the
coincidence timing window and are recorded as a single
pair. This leads to incorrectly positioned LORs and thus
adds a relatively uniform background to the reconstructed
images. An estimate of the random coincidence rate can be
obtained by delaying the coincidence timing window by an
interval relatively large to its width. Delayed coincidences
cannot be true or scattered events, since photons of the
same positron annihilation will always be detected within a
few nanoseconds of each other, but the rate of random
coincidences will be the same in the delayed and the
original window. This number can be subtracted in real
time from the total number of coincidences for the detector
pair to correct for randoms. This, however, will increase
the statistical noise level of the corrected images, since the
variance of the number of random counts is added to the
variance of the uncorrected counts. Other methods use
‘smoothed delays’, in which the delayed coincidences are
acquired in a separate and thereafter smoothed sinogram, or
estimations based on singles rates [58].
One or both photons arising from one positron annihi-
lation might be Compton scattered by the tissue within the
gantry, leading to mispositioned LORs. This leads to a hazy
background activity concentration, generally highest in the
centre of the image. The percentage of scattered events
detected in 3-D PET might approach 60–70% of all
coincidences. The attenuation data can be used to estimate
the number of scattered photons as for 511 keV photons
virtually all attenuation is due to the Compton effect [51].
Another method is by extrapolation of the projection
profiles immediately outside the object (determined from
the attenuation data), which only represent scattered
photons as almost no positron annihilations occur in air.
This scatter distribution profile can be subtracted from the
projections prior to image reconstruction [59]. A study of
cerebral FDG PET describes that all the pharmacokinetic
rate constants of glucose metabolism are overestimated due
to photon scatter up to 10–30% (in decreasing magnitude:
K1,K i,k 2,k 3 and k4). MRglc is 12–30% higher when no
scatter correction is applied [60].
At high count rates effects of system recovery after
detection of a photon are piled up leading to dead time.
Systems can either be non-paralysable (i.e. any event within
the dead time will not be counted) or paralysable (i.e. this
event will furthermore restart the dead time). Empirical
dead time models can be used in which the observed count
rate as a function of radioactivity concentration is measured
for a range of object sizes at different energy window
widths, but other methods are under investigation [61].
If all previously mentioned corrections are applied, the
number of counts per voxel in the reconstructed images is
directlyproportional totheactivityconcentrationofthat voxel.
Calibration to absolute concentrations can be performed by
scanning e.g. a cylinder containing a uniform solution of
known activity concentration. The obtained calibration factor
can be used for absolute quantification of the images.
It can be concluded that standardization of PET
acquisition is highly important. Images should be acquired
in a normoglycaemic (fasting) state. When using insulin to
reverse hyperglycaemia, this should be injected at least but
preferably longer than 1 h before the FDG. The distribution
period should be held within narrow limits (55–65 min).
The effect of prehydration and diuretics led to recommen-
dations advocating standardization. For dynamic acquisi-
tion, however, the practicability of forced diuresis should be
considered. Patient motion leads to underestimation in the
measured SUVor MRglc and should therefore be prevented.
To prevent muscle uptake and uptake in BAT, the waiting
room should be kept warm and the patient should be
instructed to minimize exercise. The effect of benzodiaze-
pines is doubtful and recent literature suggests the use of
beta-blocking agents when uptake in BAT is interfering
interpretation of the images.
The administered FDG activity should be standardized,
dependent on acquisition method and patient body weight and
kept within narrow limits (<10%). When using CTattenuation
correction, quantification in areas around (metal) artefacts
should not be performed. Likewise, quantification of lesions in
cases of spatial mismatch between PET and CT should not be
performed. Even though the effect of contrast agents on SUV
may be small, the bias introduced in the blood pool used for
pharmacokinetic modelling is large and therefore its use is
discouraged. Whenever possible, acquisition should be per-
formed with the arms outside the FOV to prevent effects of
truncation, beam hardening and increased photon scattering.
For reliable quantification, the scanner should be normalized,
1414 Eur J Nucl Med Mol Imaging (2010) 37:1408–1425(cross-) calibrated and corrections for photon attenuation,
randoms, scatter and dead time should be performed.
Tomographic reconstruction
Analytical algorithms (e.g. filtered backprojection, FBP) are
almost completely replaced by iterative statistical algorithms
(e.g. ordered subset expectation maximization, OSEM) for
tomographic reconstruction of acquired coincidence events
to quantifiable images. Iterative reconstruction has a number
of potential advantages that make it attractive in comparison
with analytical methods. Analytical algorithms have the
intrinsic, limiting assumption that measured data are perfect-
ly consistent with the object, which is never true in practice
due to noise and other physical factors (e.g. attenuation). In
contrast, iterative algorithms can incorporate a priori infor-
mation such as the statistical distribution of the coincidences
and position-dependent spatial resolution. Important adjust-
able parameters for tomographic reconstruction are the
matrix size (the number of voxels in the transaxial plane of
the reconstructed images) and the reconstruction smoothing
filter. For iterative algorithms also the number of iterations
(the number of times the estimate of the real object is
updated) and the number of subsets (the number of
projections updated simultaneously in each iteration, in
OSEM iterative reconstruction only) need to be defined.
Analytical versus iterative reconstruction
Studies comparing the difference of FBP to OSEM on
quantification of glucose metabolism [62–64] all report
higher SUVs for OSEM as compared to FBP. This might
not only be due to the reconstruction algorithm but also
caused by different attenuation correction techniques (SAC
with OSEM vs MAC with FBP) and by different reconstruc-
tion filters used [63, 64]. Similar [65] or slightly lower (2.3%)
[66] SUVsmean for different tissues are found in OSEM
compared to FBP, using the same method of attenuation
correction. This negligible effect might be due to the higher
noise levels in FBP reconstructed images, leading to different
ROIs defined on FBP compared to OSEM reconstructed
images: when the same ROIs are used on both images, no
significant differences are found [11]. Apart from noise, also
a difference in resolution may cause the dissimilarity in
quantification: higher uptake values and MRglc are found in
tumours (+14%), brain (+2 to +4%) and heart (+15 to +21%)
for OSEM than for FBP, which is almost completely
reversible by equalizing the image resolution by smoothing
with a 5-mm FWHM Gaussian kernel [67].
When specifically looking at the IDIF of the left ventricle
and ascending aorta, good agreement between OSEM and
FBP is observed for the first 5 min of the scan, but for the last
30 min of a 1-h scan, OSEM-derived IDIFs result in 30%
higher activity concentrations for the ascending aorta com-
pared to those derived by FBP [67]. It was concluded that
OSEM causes bias in regions located within a hotter
background, especially relevant for determination of an IDIF.
Activity concentrations of IDIFs in the ascending or descend-
ing aorta of FBP reconstructed images are within 5% of the
arterially sampled, leading to similar results for Patlak MRglc
using either this IDIF or arterial sampling [48, 68].
Parameters of iterative reconstruction
The number of subsets has only a small effect on the SUV
in phantom experiments when the product of iterations and
subsets is kept constant. A low number of iterations (1 or 2)
results in poor recovery of tumour activity concentrations.
Further increase of the number of iterations does not
improve the accuracy of quantification of glucose metab-
olism of lesions with an SUV higher than 5, but mainly
results in an increase of image noise. When the SUV is
lower than 5, large variability in SUV is seen as a function
of the number of iterations [29]. In a study of 50
oncological patients, the SUVmean in images reconstructed
with 28 subsets and a varying number of iterations was
systematically increased. This effect was very small after 5
iterations (<1% change between 5 and 40 iterations) [7].
Image matrix size influences both noise (smaller number of
counts per voxel in larger matrices) and spatial resolution in
phantom experiments [8]. The recovery of the activity
concentration in the spheres of a phantom is better when the
matrix size is increased from 128∙128 (voxel size ∼5∙5m m )t o
256∙256 (voxel size voxels ∼2.5∙2.5 mm). This dependency is
smaller when the smoothing kernel is larger (8 vs 5 mm full-
width at half-maximum, FWHM). This can be explained since
the image resolution (5 or 8 mm FWHM) is not at least twice
the size of the voxel size (violation of the Nyquist principle),
which can be solved by increasing the matrix to 256∙256.
It can be concluded that iterative reconstruction can be
used for quantification in oncology. For pharmacokinetic
analysis of two-compartment models, the IDIF of the left
ventricle seems to be sensitive to spill-in and the use of the
aorta is preferred. Care should be taken not to overiterate,
which only adds noise, which is especially cumbersome in
pharmacokinetic rate constant estimation. Too few itera-
tions however will lead to loss of high spatial frequency
features, such as resolution and heterogeneity. The matrix
size should be chosen not to violate the Nyquist criterion.
ROI definition
FDG uptake or metabolism is determined in an ROI, which
can be the hottest voxel within the lesion (ROImax), but can
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of 4.0: ROI4.0), on a relative threshold (e.g. >50% of
maximum voxel value within the ROI: ROI50%), on a
manually placed fixed volume (e.g. 1 ml sphere:
ROIsphere:1 ml) or adaptive (e.g. relative threshold level:
ROIRTL). Further refinements can be introduced such as
applying a relative threshold of the background subtracted
maximum voxel value [e.g. >50%∙(maximum background)
above background: ROI50%(B+max)]. The best ROI is
dependent on its goal: when used to quantify tumour
FDG uptake or metabolism, the ROI that yields the best
correlation with clinical outcome is preferred. In other
situations (e.g. radiotherapy target planning), the exact
volume and position of the ROI are more important. Since
all but the fixed volume ROI are dependent on the
maximum voxel value, the shape and size of these ROIs
are dependent on all earlier mentioned factors influencing
the SNR.
The influence of the ROI definition on the accuracy of the
SUV was determined in a phantom study comparing ROI50%,
ROI70%,R O I 50%(B+max),R O I max and ROIsquare:15 mm [8]. As
expected, the recovery coefficient increases for all ROI
definitions as a function of the lesion size. There is a strong
dependency of SUV on SNR, with a high SNR leading
towards a positive bias for the maximum voxel value and thus
overestimation of SUVs calculated with an ROI dependent on
this maximum voxel value (all but ROIsquare:15 mm). The
effects of the ROI method on the accuracy of SUV
determination are trivial: ROI70% and ROI50% are about 15
a n d3 0 %l o w e rt h a nR O I max, respectively, and ROI50%(B+max)
is in between: close to ROI50% for high tumour to background
ratios and close to ROI70% for a low tumour to background
ratio. Overall, ROI50% seems to be most accurate for high-
resolution (noisy) data and ROImax seems to be most accurate
for smoothed (low-noise) data. The fixed volume ROI
(ROIsquare:15 mm) performs worst since it includes a significant
number of non-tumour voxels, especially in smaller lesions
[8].
In an ROI definition study of response assessment of lung
cancer comparing ROImanual,R O I max,R O I circle:15 mm,R O I 75%
and ROI50% it is mentioned that ROIs50% in lesions with low
uptake are often discarded on post-chemotherapy scans
because of inclusion of non-tumour tissue [11]. Nevertheless,
an excellent test-retest reproducibility of the volume of
ROI50% on 2 consecutive days is reported (ICC=0.99). The
fixed volume-based ROI (ROIcircle:15 mm) shows best repro-
ducibility with respect to SUVmean (ICC=0.95), but the
reproducibility of ROI50% is also very high (ICC=0.91).
Due to the partial volume effect (PVE [69]), the
isocontour level for proper whole-lesion delineation is lesion
size dependent. Previously, in phantom measurements the
exponential relation between lesion volume and threshold
(percentage of maximum value) was determined for five
different contrast levels and used on metastatic lung lesions
yielding highly correlated ROI and CT volumes (correlation
coefficient: 0.999) [70]. A more sophisticated approach was
promoted later in which a 3-D sphere was convolved with a
symmetric trivariate Gaussian point spread function [71].
This equation for background-subtracted relative threshold
level (RTL) as a function of tumour radius and image
resolution is independent of the tumour to background ratio
and is used iteratively on PET data until the measured PET
volume and threshold match. In patients the technique seems
feasible and similar dimensions are achieved as pathological
examination of liver metastases.
In conclusion, a number of methods for definition of the
region of interest are described in the literature. The
maximum voxel value is preferable in data with limited
noise, does not require specialized algorithms and does not
suffer from interobserver variability. A threshold-based ROI
can provide reproducible quantification of glucose metab-
olism with better accuracy in noisy images. The NEDPAS
guidelines recommend the use of an ROI41%(B+max), but to
increase the (background-corrected) threshold when no
meaningful tumour volume definitions are provided in
lesions with a low signal to background ratio. They stress
that the maximal voxel value should always be noted [14].
Quantification
Quantification of FDG uptake or metabolism of the tissue
within the ROI can be performed on several levels of
complexity: semiquantitatively or quantitatively (from
dynamic FDG PET acquisitions) using pharmacokinetic
analysis of two-compartment models.
Semiquantitative methods
The simplest method to quantify tracer uptake is by
calculating tumour to non-tumour ratios (T/N) using a
reference tissue, which may be difficult to define or may
have limited uptake (resulting in a relatively high noise
level). Furthermore, uptake in this reference tissue may be
influenced by factors such as therapy, and therefore T/N
ratios can change without change in tumour biology.
Since tracer uptake is directly related to body volume of
the patient and the AA present in the subject at start time of
the scan, measured uptake (Bq∙cm
−3) should be normalized
for these factors. This results in an SUV and is in older
papers being referred to as differential absorption (or
uptake) ratio (DAR, DUR). The least complicated normal-
ization is by AA and patient body weight (SUVBW). For
uniform tracer distribution the SUV is 1.0 and an SUV >1
implies tracer accumulation. As sceptically reviewed by
Keyes [72], body composition and habitus are a source of
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other tissues. Therefore, other definitions for volume of
distribution of FDG are proposed. It is observed that
SUVBW is still positively correlated to body weight for
normal tissues, leading to SUVsBW in heavy weighted
patients up to twice that of normal patients. However, the
SUVLBM is weight independent [73]. Others [74–76]
provide evidence that the overestimation of SUVBW of
liver tissue in heavy oncological patients can be prevented
using BSA (body surface area) as normalization factor. See
Table 3 for definition of various types of SUV.
Another factor related to SUV is the plasma glucose
level. It is unlikely that the effects of variations in glucose
level only hold true for hyperglycaemic conditions. The
decreased uptake values during hyperglycaemia can be
adjusted for by normalizing the SUV for plasma glucose
divided by the population average [100 mg∙l
−1
(≈5.6 mmol∙l
−1)] [17].The NEDPAS guidelines [14] support
a normalization for glucose concentration based on plasma
glucose concentration (mmol∙l
−1) divided by the population
average (5.0 mmol∙l
−1).
Quantitative measures
Analysis of two-compartment models by non-linear
regression
Dynamic PET studies provide the opportunity to perform
pharmacokinetic analysis of two-compartment models of
glucose metabolism. In addition to the PETsignal [CPET (t)],
the tracer concentration in the arterial blood plasma should
also be measured [Cplasma (t)], which is a drawback
compared to static methods in which only the SUV is of
interest. Another drawback of dynamic acquisition is that
only one FOV (typically ∼15–20 cm) can be taken into
account; therefore, in metastasized disease not all lesions
can be quantified simultaneously.
Since deoxyglucose-6-PO4,i nc o n t r a s tt og l u c o s e - 6 - P O 4,
cannot be catabolized further and does not diffuse across cell
membranes, metabolism can be simplified to a two-
compartment model (Fig. 2)w i t hf o u rr a t ec o n s t a n t s .T r a c e r
kinetic modelling is based on several key assumptions
including the tracer principle (i.e. negligible concentration of
the tracer), steady-state assumption (i.e. metabolic processes
are at steady state during measurement), tissue homogeneity
and instantaneous mixing assumption (i.e. homogeneous
tracer distribution within each compartment), linearity as-
sumption (i.e. rate constants are independent of tracer
concentration: first-order kinetics) and the tracer dynamic
assumption (i.e. the tracer behaves similarly to the substance
under investigation) [77]. Moreover, it is assumed that the
extraction of FDG from the plasma normally is low enough
for the delivery of FDG to be independent of blood flow.
According to the Michaelis-Menten hypothesis, an
intermediate complex is formed between the substrate (S)
and the transporter or enzyme, which is then converted to
the chemical product (P) with release of the transporter or
enzyme. The reaction rates of these processes are described
by kS!P ¼ Vmax   S ½    S ½  þ Km ðÞ
 1 in which Vmax is the
maximum rate of the reaction and Km (the Michaelis
constant) is that concentration of the substrate ([S]) which
leads to 0.5∙Vmax. This is clearly a non-linear relation, but it
is still possible to use linear tracer compartment models if
an alternative substrate (S
*) is competing for the transport-
er/enzyme, the concentration of which is of a much lower
value than of S [78, 79]. In this case, the reaction rate of the
original substrate is (approximately) unaltered and the
reaction rate of the tracer can be described as: kS*!P* ﬃ
V*
max   S*
hi
  Km   K*
m   S ½  þ Km ðÞ
    1
which is a linear
function of [S
*] as long as S* ½  << S ½  . Therefore, the two-
compartment model with four pharmacokinetic rate con-
stants (Phelps 4K model) can be expressed by the following
differential equations [80]:
dCfreeðtÞ
dt
¼ K1   CplasmaðtÞ  k2 þ k3 ðÞ   CfreeðtÞþk4   CboundðtÞ
) CfreeðtÞ¼
K1
a2   a1
 ½k4   a1 ðÞ   e a1 t
þ a2   k4 ðÞ   e a2 t  CplasmaðtÞ
ð1Þ
Table 3 Equations to normalize the SUV
Body weight (BW) SUVBW ¼ CFDG
AA   BW   1000
Body surface area (BSA) SUVBSA 10 6m 1   
¼ CFDG
AA   0:007184   BW0:425   h0:725 ðÞ
†
Lean body mass (LBM) Male: SUVLBM ¼ CFDG
AA   48:0 þ 1:06   h   152 ðÞ ðÞ   1000
Female: SUVLBM ¼ CFDG
AA   45:5 þ 0:91   h   152 ðÞ ðÞ   1000
Body weight and plasma glucose SUVBWþglc ¼ CFDG
AA  
Cglc
5:0   BW   1000
Various methods for normalization of FDG uptake for different parameters representing distribution volume
AA administered activity, corrected for decay occurring between time of measurement and start time of scan in Bq, CFDG average measured FDG
activity concentration in region of interest in Bq∙cm
−3, BW: body weight in kg, Cglc glucose concentration in venous plasma in mmol∙l
−1, h height
in cm, SUV standardized uptake value in g∙cm
−3 (often SUV is presented dimensionless since it is based on the density of water (ρ=1.0 gcm
−3).
SUVBSA has a different unit (i.e. 10
−6 m
−1); therefore, it is to be rescaled according to the ratio SUVBW∙SUVBSA
−1, which is 3.42∙0.083
−1 =
41.2 kg m
−2 in one study [74]
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dt
¼ k3   CfreeðtÞ k4   CboundðtÞ
) CboundðtÞ¼
K1   k3
a2   a1
  e a1 t   e a2 t ðÞ   CplasmaðtÞ
ð2Þ
Where ‘ ’ stands for the operation of convolution and
a1;2 ¼ 1
2   k2 þ k3 þ k4  
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
k2 þ k3 þ k4 ðÞ
2   4   k2   k4
q   
.
The sum of the activity concentrations in both compart-
ments plus a fraction of the plasma activity concentration
[Vb·Cplasma (t), with Vb the blood volume fraction] are
measured within the ROI by the dynamic PET acquisition:
CPETðtÞ¼ 1   Vb ðÞ   CfreeðtÞþCboundðtÞ
  
þ Vb
  CplasmaðtÞð 3Þ
Therefore, when the plasma input function is known, all
five free parameters of FDG metabolism (K1,k 2,k 3,k 4 and
Vb) can be estimated using non-linear least squares fitting
of CPET(t).
The original irreversible model (Sokoloff 3K model) did
not incorporate k4 [81] since the rate of hydrolysis of FDG-
6-PO4 by glucose-6-phosphatase activity is negligible in
mammalian tissues, except for liver tissue [82]. This is
verified in further studies [83], which compare the residual
sum of squares of fits with and without k4 by the Akaike
Information Criterion [84] and Schwarz Criterion [85].
These statistics reward goodness of fit but depreciate the
number of free parameters of the model (the lowest value
denotes the model that best explains the data with a
minimum of free parameters). Moreover, simulation studies
caution that a k4 might result from tissue heterogeneity
rather than real dephosphorylation [86]. Therefore, current-
ly most studies use the simplified three-rate constant
(Sokoloff 3K) model. With k4=0, Eqs. 1 and 2 simplify
to:
dCfreeðtÞ
dt
¼ K1   CplasmaðtÞ  k2 þ k3 ðÞ   CfreeðtÞ
) CfreeðtÞ¼K1   e  k2þk3 ðÞ   t   CplasmaðtÞ
ð4Þ
dCboundðtÞ
dt
¼ k3   CfreeðtÞ)CboundðtÞ
¼
K1   k3
k2 þ k3
  1   e  k2þk3 ðÞ   t
  
  CplasmaðtÞ
ð5Þ
The ratio of the phosphorylation rates of FDG (MRFDG)
and glucose (MRglc) equals both the ratio of fluxes between
the compartments of free and bound substrates (Eq. 5) and
the ratio of the Vmax,K m and concentration of both the
intracellular free tracer and the natural substrate:
MRFDG
MRglc
¼
k3;FDG   Cfree;FDGðtÞ
k3;glc   Cfree;glcðtÞ
¼
Vmax;FDG   Km;glc   Cfree;FDGðtÞ
Vmax;glc   Km;FDG   Cfree;glcðtÞ
ð6Þ
In contrast to analogue tracers (such as FDG) when
direct isotopic substitution labelling of glucose is used (e.g.
[
11C]-glucose), the Vmax and Km for both substrates are
essentially the same and Eq. 6 would reduce to a simple
ratio of concentrations of FDG and glucose. In the
condition where Cplasma(t) of glucose and FDG is constant,
Eq. 6 can be written as:
MRFDG   Cplasma;FDG   F
    1
MRglc   Cplasma;glc   F
    1 ¼
Vmax;FDG   Km;glc   lFDG
Vmax;glc   Km;FDG   lglc
¼ LCFDG
ð7Þ
In which F is the blood flow and λ are the partition
coefficients Cfree   Cplasma
 1   
of both the substrates. This
ratio is called the lumped constant of FDG (LCFDG), or the
steady-state ratio of the net extraction of FDG to that of
glucose at constant plasma levels of both substrates [81].
The full operational equation is often written as: LCFDG ¼
Vmax;FDG   Km;glc   l   Vmax;glc   Km;FDG   ϕ
    1. In this λ de-
notes the ratio of partition coefficients and ϕ is the fraction
of glucose-6-PO4 that continues down the Embden-Meyerhof
pathway (i.e. regular glycolysis), which is normally quite
close to 1.0. The value of the LCFDG can be determined by
simultaneous measurement of MRglc (e.g. by [
11C]-1-glucose)
and MRFDG [87], independent determination of all six
parameters of the LC or by the ratio of fractional arteriove-
nous differences for the two substrates [81, 88].
In the steady-state condition of the compartment of free
intracellular FDG, the flux into this compartment is
balanced by the flux out dCfreeðtÞ dt 1   
FDG ¼ 0
  
, the
MRglc can be estimated from Eqs. 5 and 7:
MRglc ¼
dCbound;glcðtÞ
dt
¼
MRFDG
Cplasma;FDG
 
Cplasma;glc
LCFDG
¼
K1   k3
k2 þ k3
  
FDG
 
Cplasma;glc
LCFDG
ð8Þ
Fig. 2 The two-compartment model for FDG catabolism. Cplasma (t)
the activity concentration of FDG in the blood plasma, Cfree (t) the
intracellular activity concentration of free FDG, Cbound (t)t h e
intracellular activity concentration of FDG-6-PO4, K1, k2, k3 and k4
rate constants (see Table 1), CPET(t) the measured PET signal which is
a combination of Cfree(t), Cbound(t) and a fraction (shaded area, Vb)o f
Cplasma(t). The dotted line symbolizes the cell membrane
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carcinoma using the Sokoloff (3K) model, it was shown
that parameter estimation by non-linear least squares fitting
of 30-min dynamic data yielded essentially the same results
for K1,k 2,k 3 and Ki,( R
2=0.918, 0.937, 0.785 and 0.924,
respectively, with mean relative differences varying 9–25%)
compared to a 60-min protocol [89].
Primary, glucose metabolism (and thus the LCFDG) are
determined in the normal (rat) brain [18, 78, 87]. In this
field it has been shown that the use of a single LCFDG suits
only considering the conditions during which it was
determined. The LCFDG is dependent on the time between
tracer injection and measurement, surely changes in any
disease with an enzymatic component and probably varies
with regional glucose concentrations and in conditions of
ischaemia, hypoglycaemia, the method of anaesthesia, age
(adult or developing) and species of the subject under
investigation. Due to the heterogeneity of neoplasia, these
limitations are far greater and for many tumours the LCFDG
is not known. As perfectly summarized elsewhere, calcu-
lations of MRFDG can be used if one is interested in
comparative measurements (e.g. metabolic changes over
time, during treatment, between a diseased or normal tissue
or between different physiological states), assuming the
LCFDG of the tissue under investigation remains unchanged.
In cases in which the true MRglc needs to be determined
from FDG results, then one must measure the LCFDG in the
particular experimental setup [18]. Studies of the LCFDG in
oncology are very limited and reports of determination of
the LCFDG of non-glioma malignant tissues are lacking to
this date.
Patlak graphical method
Patlak et al. [90] derived a graphical method (often called
Patlak analysis, Patlak-Rutland or Gjedde-Patlak plot) that
uses linear regression to analyse pharmacokinetics de-
scribed by any compartment model with at least one
irreversible transport step or reaction (‘trapping’ of FDG
due to k4=0 min
−1). It further assumes that all the reversible
compartments must be in equilibrium with the plasma,
which in practice only occurs when dCplasma (t)/dt is small
enough for these tissue compartments to follow. Combining
Eqs. 3–5,w i t hKi ¼
K1 k3
k2þk3 leads to:
CPETðtÞ
CplasmaðtÞ
¼ Ki   1   Vb ðÞ ðÞ  
R t
0 Cplasma t ðÞ dt
CplasmaðtÞ
 !
þ
1   Vb ðÞ   K1   k2
k2 þ k3 ðÞ
2 þ Vb
 !
ð9Þ
Linear regression of the plot CPETðtÞ CplasmaðtÞ
 1 vs R t
0 Cplasma t ðÞ dt   CplasmaðtÞ
 1 (“Patlak space” or “funny time”)
results in slope: Ki   1   Vb ðÞ , from which, with an estimated
Vb,M R glc can be computed. Simplification of the problem of
solving differential equations by non-linear optimization to
an approach amenable to linear regression avoids many
problems inherent in the former approach: sensitivity to
noise in the time-activity concentration curves, parameter
covariance, local minima in the approximate solution to the
differential equations and dependence of parameter estimates
on starting guesses. As a trade-off only the Ki,b u tn o tt h e
individual kinetic parameters, is estimated. An example is
provided in Fig. 3.
Linearity in Patlak space is reached in conditions where
the plasmaFDGconcentrationisconstant,but since Cplasma(t)
continues to decrease due to irreversible cellular uptake and
renal clearance, this situation is never fully met. In good
approximation, onset of linearity is usually attained 10–
15 min after the bolus injection. It is shown that MRglc
determined by Patlak analysis over different intervals is
highly similar compared to the Sokoloff (3K) model (all
R
2≥0.951). ROIs were defined on the last three time frames
(45–60 min), which is a limitation of this study; in shortened
protocols, tumour ROIs have to be drawn at earlier time
points, in which the contrast is lower, leading to different
ROIs which likely will produce less accurate MRglc [83].
Another way of shortening acquisition duration is by
combination of an initial 10-min dynamic scan with a single
static time frame 56–60 min after tracer injection [91].
Highly similar values for Ki between full dynamic and a
shortened dynamic acquisition are described (R
2 of non-
linear regression=0.815). In practice the ROIs need to be
repositioned since the patient leaves the gantry between both
acquisitions.
Adaptations to pharmacokinetic models
Variations to the previously mentioned pharmacokinetic
models have been reported frequently [92–98]. A variation
to the Sokoloff 3K model with six parameters uses a
reference region outside the tumour to account for the
normal tissue within the tumour ROI (2 ROIs 6P model). In
simulation studies it was found to adequately describe
tumour pharmacokinetic rate constants of two-compartment
models regardless of the amount of normal tissue within the
ROI. A drawback of the technique is that reference tissue
must be available [92].
Many variations to the Patlak graphical method are
reported [93–98]. Wong et al. [93] describe a technique in
which they create three sequential images (each 15 min
duration) starting 10 min after FDG injection combined
with three arterialized venous samples taken at the mid-time
of each scan. This method pre-empts the need for continued
sampling and showed Ki to be within 3–4% of the values
obtained by regular Patlak analysis. Another variation
Eur J Nucl Med Mol Imaging (2010) 37:1408–1425 1419computes lesion Ki from the mean of the per voxel Ki for
which the correlation coefficient of the Patlak plot is above
a threshold [94]. This technique was further adapted by
defining a 2-D ROI on a summed image of all correlation
coefficient-constrained planes containing the lesion. This
ROI was propagated over the planes containing the lesion
in which the parameters of interest were determined. The
authors conclude that this technique (total lesion evaluation
method, TLE) is less ROI dependent and also incorporates
therapy-related volume changes and is especially suitable
for therapy response monitoring [95]. A simplified kinetic
method (SKM) is advocated [96], assuming a uniform input
function, based on fitting the input function of control
patients with a triexponential decay function. The SKM
allows MRglc to be calculated from a static image and one
late venous blood sample. It was shown in lung cancer
patients that the SKM was an improvement over the SUV
and approaches the MRglc, calculated by non-linear least
squares. A hybrid method of Patlak and SKM shows less
bias and variability than either technique alone. For this
method six time frames (each 5 min, 25–55 min post-
injection) are acquired. By using every other time frame (3
data points) or every third time frame (2 data points) this
method can be used to up to three fields of view [97]. The
last method mentioned is based on the relation between Ki
and SUV, average plasma clearance rate and the initial
distribution volume of FDG (Sadato method). Estimated Ki
and SUV are compared with Patlak Ki, leading to the
conclusion that the estimated, non-invasively determined Ki
is a better indicator of tumour uptake than the SUV [98].
Hoekstra et al. reviewed [99] and compared [83]3 4
variations of previously mentioned methods to obtain
glucose consumption (2 T/N, 12 SUV, 2 Sadato, 2 SKM,
5 Patlak, 10 TLE and one “2 ROI, 6P” variations) on 30
randomly selected dynamic FDG PET scans in 19 lung
cancer patients. Since incorporation of k4 did not improve
fits, the Sokoloff 3K model was used as gold standard. The
reliability of the gold standard was considered high since
the test-retest variability (ICC=0.95) and intra- and inter-
observer variability (ICC=0.98 for both) were small. Of the
34 models tested, 10 met the required minimal correlation
with the gold standard (R
2>0.95). They concluded that the
best simplified options are SUVBSA+glucose (40–60 min or
50–60 min post-injection), Sadato method based on BSA
and Patlak graphical analysis (10–60 min post-injection).
Similarly, Lammertsma et al. [100] pooled the results of
Fig. 3 Quantitative analysis of a T2 adenocarcinoma of the right superior lung lobe (left top). Right top, time-activity concentration curves. Left
bottom, analysis of two-compartment models by both Sokoloff 3K and Phelps 4K model. Right bottom, Patlak graphical analysis
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monitoring in lung [83], breast [101] and gastro-
oesophageal [102] cancer (in total 170 FDG PET studies)
and show excellent correlation with the Sokoloff 3K
model of Patlak MRglc (ICC=0.98), SKM (ICC=0.94),
SUVBSA+glucose (ICC=0.91) and SUVBSA (ICC=0.91).
They conclude that although Patlak MRglc has the best
correlation with the gold standard, it remains to be proved
that these findings are of clinical relevance. Changes found
by SUV estimation may still represent a relevant response
[103, 104].
Input functions
For all previously described fully quantitative measures of
glucose metabolism, the arterial plasma input function [IF
or Cplasma (t)] of the tumour should be known. Different
approaches to obtain this IF have been described in the
literature. Since it is impossible to sample the artery directly
vascularizing the tumour, the gold standard is serial arterial
sampling of a superficial artery (e.g. the radial artery) after
which the activity concentration of the plasma derived by
centrifugation can be determined [105]. Alternatives to
serial arterial sampling with less complications [106] or less
radiation burden to the personnel are: (arterialized) venous
blood sampling [107], use of an IDIF [48, 108], modelling
of a population-based IF [109–111] or extraction of IF
using mathematical segmentation methods [112].
To overcome the time-dependent ratio of arterial and
venous blood activity concentration, the heated hand
procedure, which shunts the arterial blood to the venous
system, can be performed [107]. In Patlak analysis, the use
of arterialized venous blood shows a net effect of ∼10%
overestimation of Ki and ∼5% overestimation of MRglc
compared to the gold standard of arterial sampling. IDIFs
of the ascending (ICC=0.98) or abdominal (ICC=0.96)
aorta show better Patlak MRglc correlation than IDIFs of the
left ventricle (ICC=0.94) [48, 108], but due to the PVE the
recovery of activity concentrations in the aorta is less than
one, causing an underestimation of the FDG activity
concentration. A left ventricle IDIF shows positive bias,
since the PVE caused a hot myocardium to spill-in activity
in later time frames [48] leading to an underestimation of
MRglc of 16.2–17.5% [113]. Another drawback of the IDIF
is that it is a measure of whole blood activity concentration,
which is known to be lower than in plasma and not constant
over time [107]. Population-based curves reduce the need
for blood sampling and moreover can be used in body areas
where IDIFs are not feasible. They can be based on
averaging normalized blood curves or on fitting to a
proposed equation [109, 110]. Patlak-based MRglc obtained
by population-based curves overall show high correlation
with the gold standard (R
2>0.984) [109]. Usage of
mathematical tissue segmentation results in whole blood
activity concentrations as well [112, 114], but it leads to an
image-derived whole blood IF with similar drawbacks as an
IDIF.
For estimation of pharmacokinetic rate constants of two-
compartment models, the exact timing (time delay) and
shape (dispersion) of the IF are needed. When it is
measured by sampling [82], this does not necessarily reflect
the supply of the tracer to the lesion. The time delay can be
corrected for, but the dispersion of the IF results from the
impulse response characteristics of the distributing system
of the patient and is therefore difficult to predict [79]. These
factors complicate the use of pharmacokinetic analysis of
two-compartment models and therefore frequently IDIFs of
a large blood pool close to the tumour are used [49, 50].
The effect of time delay and dispersion is of negligible
relevance for Patlak MRglc estimation, since the Cplasma (t)
in the Patlak equation is relatively constant in the period of
linear regression and the integral of Cplasma (t) is almost not
affected.
Concluding, for clinical practice and most research into
the value of quantification of FDG PET, the SUVmax and
SUVs of isocontour-based ROIs are most relevant. They
can be performed whole body, pre-empt the need of an IF
and can be obtained from static images. In special situations
FDG metabolism can be quantified using dynamic acqui-
sition, preferably using IDIFs of the ascending aorta. Even
though these result in absolute quantification of FDG
influx, they are limited in calculation of ‘real’ MRglc due
to the indefinite value of the LCFDG.
Repeated measures studies
Quantitative FDG PET is not only useful as a single
measurement (e.g. for treatment stratification), but repeated
measurements before, during and after treatment may be
used for early response assessment of therapy. For this
purpose a new quantification parameter is introduced,
defined as the product of the SUV and tumour volume
(total lesion glycolysis, TLG) [115]. Even though the
ΔTLG is used in a small number of recent studies [116,
117], this response parameter needs further evaluation
before it can be recommended for routine use, since it does
not perform better than ΔSUV alone in all studies [116].
Measured tumour response is nearly independent of the
ROI definition, since most factors contributing to bias and
noise cancel out in calculation of the relative change [8,
11]. However, when the tumour volume changes signifi-
cantly, the PVE can play a role which cannot be cancelled
by measuring relative effects [8]. For matter of reproduc-
ibility, threshold-based ROIs are recommended for repeated
measures studies, with a test-retest reproducibility of the
Eur J Nucl Med Mol Imaging (2010) 37:1408–1425 1421SUV of 1–13±6–12% [11, 118–120], of Ki of 10±8% and
of K1,k 2 and k3 of 24–42±13–31% [119]. Due to the
magnitude of the day-to-day variation, changes in quanti-
fication of SUV±15–20% (i.e. 2 standard deviations) are
within the reproducibility limits of this method of quanti-
fication and therefore should be considered as stable values.
The robustness of variations of the ΔSUV (%) was
shown in gastric carcinoma patients neoadjuvantly treated
with cisplatin-based chemotherapy [10]. The authors
conclude that in gastric carcinomas the prediction of
response to chemotherapy on the basis of relative tumour
SUV changes is not essentially influenced by any of the
methodological variations investigated (incubation period
40 or 90 min, reconstruction method FBP or OSEM and
various SUV normalizations). However, phantom experi-
ments reveal a difference between institutions for SUV
quantification up to 30%, which can be improved by
calibration [29]. This is especially important when baseline
and follow-up scans are performed in different settings or
institutions, underlining the need for standardization [14].
Conclusion
Apart from hardware issues and sources of error, many
methodological and biological factors influence quantification
in FDG PET. For multicentre investigation therefore these
parameters must be standardized and intercentre calibration
has to be performed. In general, the relative simplicity of
semiquantitative quantification by SUV seems to outweigh its
drawbacks, providing that the process from acquisition till
quantification is standardized. Repeated measures studies
seem less dependent on most factors influencing quantifica-
tion as they cancel out in calculation of relative treatment
effects providing that the methodology at the baseline scan is
repeated for the follow-up scan. Pharmacokinetic quantifica-
tion is a sophisticated and rather complicated method and is
therefore mainly applied in a research setting.
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